8-K: Qualigen Gets Final Nasdaq Extension for Equity Rule

Qualigen Therapeutics received a final extension from Nasdaq to regain compliance with the $2.5 million stockholders' equity rule, with a deadline tied to its Q3 2025 filing.

Summary

• Qualigen Therapeutics, Inc. received a written decision from the Nasdaq Hearings Panel on September 4, 2025, regarding its compliance with listing rules.
• The Panel granted a final exception for the company to demonstrate compliance with Nasdaq Listing Rule 5550(b)(1), which requires maintaining stockholders' equity of at least $2.5 million.
• Compliance must be shown upon the filing of its Quarterly Report on Form 10-Q for the quarter ending September 30, 2025, which is due no later than November 15, 2025.
• The company previously reported stockholders' equity of approximately negative $1.6 million in its Form 10-Q for the period ended June 30, 2025.
• A private placement of Series A-3 Preferred Stock closed on July 28, 2025, generating net proceeds of approximately $4.3 million, which the company believes materially improved its equity position.
• An amended promissory note with Marizyme, Inc. on August 21, 2025, resulted in a positive adjustment to stockholders' equity of more than $600,000.
• The Panel noted that actions taken after the July 28, 2025 deadline could not be considered for demonstrating compliance as of that specific date.
• No additional time will be granted if the company fails to demonstrate compliance upon filing the Q3 2025 report.
• The company is now current in its SEC reporting obligations and has regained compliance with Nasdaq Listing Rule 5250(c)(1) (Periodic Filing Rule).

Sentiment

Score: 4

Explanation: While the company received a final extension and addressed its periodic filing compliance, the 'final' nature of the exception for the critical equity rule, coupled with the initial failure to meet the deadline, indicates significant ongoing financial pressure and a precarious listing status. The capital raise is a positive, but the underlying issue of insufficient equity persists as a major concern.

Positives

• Regained compliance with Nasdaq Listing Rule 5250(c)(1) (Periodic Filing Rule), indicating current SEC reporting obligations.
• Secured approximately $4.3 million in net proceeds from a private placement, which the company believes materially improved its stockholders' equity.
• Amended a promissory note, resulting in a positive adjustment of more than $600,000 to stockholders' equity.
• Received a final exception from Nasdaq, providing additional time until November 15, 2025, to demonstrate compliance with the Equity Rule.

Negatives

• Failed to demonstrate compliance with Nasdaq Listing Rule 5550(b)(1) (Equity Rule) by the initial July 28, 2025 deadline, having reported negative $1.6 million in stockholders' equity as of June 30, 2025.
• The Panel explicitly stated that actions taken after July 28, 2025, could not be considered for compliance as of that specific deadline.
• The granted exception is 'final', meaning no further extensions will be given if compliance is not met by November 15, 2025, increasing the risk of delisting.

Risks

• Risk of delisting from The Nasdaq Capital Market if the company fails to demonstrate stockholders' equity of at least $2.5 million upon filing its Quarterly Report on Form 10-Q for the quarter ending September 30, 2025, by the November 15, 2025 deadline.

Future Outlook

The company has been granted a final exception to demonstrate compliance with Nasdaq's $2.5 million stockholders' equity rule by filing its Quarterly Report on Form 10-Q for the quarter ending September 30, 2025, no later than November 15, 2025. Failure to meet this deadline will result in no additional time being granted, implying potential delisting.

Management Comments

• The Company believes this financing materially improved its stockholders equity position.

Industry Context

This filing highlights the ongoing challenges faced by smaller biotechnology or pharmaceutical companies, like Qualigen Therapeutics, in maintaining compliance with stringent exchange listing requirements, particularly capital-related rules. Such companies often rely on capital raises and strategic financial adjustments to sustain operations and meet regulatory thresholds, a common theme in the capital-intensive biotech sector.

Stakeholder Impact

• Shareholders: Potential for significant share price volatility due to ongoing delisting risk; dilution from the private placement.
• Investors: Increased uncertainty regarding the company's long-term listing status and financial stability.
• Employees: Potential for uncertainty if the company faces delisting or further financial distress.

Next Steps

• File the Quarterly Report on Form 10-Q for the quarter ending September 30, 2025, no later than November 15, 2025.
• Demonstrate compliance with Nasdaq Listing Rule 5550(b)(1) (Equity Rule) in the aforementioned 10-Q filing.

Key Dates

Recommendation

The company faces a critical, final deadline to meet Nasdaq's equity requirements, having already failed an earlier deadline. While a capital raise occurred, the Panel's decision highlights that it wasn't sufficient to meet the prior compliance date, and the 'final' nature of the extension indicates a high probability of delisting if the upcoming Q3 10-Q does not show compliance. This creates significant uncertainty and downside risk for the stock, making it a speculative investment with a strong potential for further value erosion.

Keywords

Qualigen Therapeutics, QLGN, Nasdaq, Delisting, Stockholders Equity, Listing Rule 5550(b)(1), Private Placement, SEC Reporting, Biotechnology, Pharmaceuticals